Summary Proinflammatory cytokines are factors that induce ubiquitin-proteasomedependent proteolysis in skeletal muscle, causing muscle atrophy. Although isoflavones, as potent antioxidative nutrients, have been known to reduce muscle damage during the catabolic state, the non-antioxidant effects of isoflavones against muscle atrophy are not well known. Here we report on the inhibitory effects of isoflavones such as genistein and daidzein on muscle atrophy caused by tumor necrosis factor (TNF)-a treatment. In C2C12 myotubes, TNF-a treatment markedly elevated the expression of the muscle-specific ubiquitin ligase MuRF1, but not of atrogin-1, leading to myotube atrophy. We found that MuRF1 promoter activity was mediated by acetylation of p65, a subunit of NFkB, a downstream target of the TNF-a signaling pathway; increased MuRF1 promoter activity was abolished by SIRT1, which is associated with deacetylation of p65. Of interest, isoflavones induced expression of SIRT1 mRNA and phosphorylation of AMP kinase, which is well known to stimulate SIRT1 expression, although there was no direct effect on SIRT1 activation. Moreover, isoflavones significantly suppressed MuRF1 promoter activity and myotube atrophy induced by TNF-a in C2C12 myotubes. These results suggest that isoflavones suppress myotube atrophy in skeletal muscle cells through activation of SIRT1 signaling. Thus, the efficacy of isoflavones could provide a novel therapeutic approach against inflammation-related muscle atrophy.
Muscle atrophy occurs by both decreased protein synthesis and increased proteolysis. In our previous studies, ubiquitinated proteins that catalyze the ubiquitin-proteasome-dependent proteolytic pathway accumulated in atrophied human quadriceps femoris muscle and the spaceflight rat gastrocnemius muscle (1, 2) . Musclespecific ubiquitin ligases encode atrogin-1 and MuRF1, potent inducers of muscle atrophy that are responsible for the increased protein degradation through the ubiquitin-proteasome-dependent proteolytic pathway. Indeed, previous reports have shown that knockout mice lacking atrogin-1 and MuRF1 are resistant to denervation-induced muscle atrophy (3, 4) . Atrogin-1 targets myogenic transcriptional and eukaryotic initiation factors, such as MyoD and eukaryotic initiation factor 3 subunit 5, suggesting that atrogin-1 plays an important role in the regulation of protein synthesis (5, 6) . In contrast, MuRF1 targets muscle sarcomere-related proteins, such as troponin I, myosin-binding protein C, actin, and myosin light chain (MLC)-1 and MLC2, suggesting that MuRF1 plays a central role in the maintenance of muscle function (7, 8) .
Proinflammatory cytokines, such as tumor necrosis factor (TNF)-a and TNF-related weak inducer of apoptosis (TWEAK), are known as inducers of muscle atrophy mediated by a ubiquitin-proteasome-dependent proteolytic pathway and as potent activators of NFkB in muscle (9, 10) . In fact, muscle-specific transgenic expression of activated IkB kinase b, which also indicates activated NFkB, leads to muscle wasting that resembles clinical cachexia whereas the inhibition of NFkB through expression of an IkBa suppressor enhances resistance to denervation-and tumor-induced muscle loss (11) . In addition, TNF-a stimulation enhances acetylation of the p65 subunit of NFkB by p300/CBP acetyltransferases, resulting in increased DNA binding and enhanced transcription of target genes (12) . A recent report suggests that SIRT1, a nicotinamide adenosine dinucleotidedependent histone deacetylase, physically interacts with p65 and inhibits transcription by deacetylating p65 at lysine 310 (13) . Therefore, deacetylation of NFkB may serve as an important target and be beneficial against muscle atrophy. Resveratrol, a natural isoflavone abundantly found in grapes and red wine, has been shown to increase SIRT1 activity in vivo and in vitro (14) . Genistein and daidzein, which are abundantly present in soy products, are also isoflavones that behave similarly to resveratrol and are well known for their estrogenic action. (15) . Recently, it has been reported that treatment with resveratrol can inhibit enhanced expression of atrogin-1 and MuRF1 through a SIRT1-dependent mechanism in C2C12 myotubes (16) . However, any effects of other isoflavones such as genistein and daidzein against muscle atrophy are still unknown.
In this study, we examined the effect of isoflavones derived from soy extracts in atrophied C2C12 myotubes. Treatment with genistein and daidzein elicited activation and increased expression of SIRT1, resulting in decreased MuRF1 expression but not atrogin-1 expression in TNF-a-treated C2C12 myotubes. In addition, genistein and daidzein prevented the decreased thickness of myotubes that TNF-a induced. Our results suggest that supplementation with isoflavones might be beneficial in the prevention of muscle atrophy caused by MuRF1 activation.
MATeRIAlS AnD MeThoDS
Plasmid DNA constructs. Mouse 3.4-kb atrogin-1 and 4.3-kb MuRF1 promoters were amplified from chromosomal DNA with synthetic primers as described previously (11, 17) . The following oligonucleotide primers were used for amplification: 5′-GGGGTACCCTTCTCCAG GCCAGTAGGTG-3′ and 5′-CTCGAGTGGTACAGAGCGC GGACGCG-3′ for mouse atrogin-1 promoter; and 5′-CT CGAGGCCAAGAGGCCTCAAACTCTCAGG-3′ and 5′-A AGCTTGTCTTGGTCTGAGGCCCCTCTGAT-3′ for mouse MuRF1 promoter. The PCR products digested with HindIII, KpnI, or XhoI restriction enzymes were subcloned upstream of the firefly luciferase gene of pGL3-Basic Vector (Promega, Madison, WI). Mouse p65 cDNA was isolated from a mouse skeletal muscle cDNA library by PCR. The isolated p65 PCR product was subcloned into the mammalian expression plasmid vector pcDNA3.1-V5 (Invitrogen, Carlsbad, CA). Point mutations were made in the template of pCDNA3.1-p65-V5 using the QuikChange site-directed mutagenesis technique of Stratagene Cloning Systems (Stratagene, La Jolla, CA). The K310R p65 mutant was generated by PCR. The mutational primers were as follows: K310R p65, forward: 5′-GAGACCTTCAGGAGTATCATGAAG-3′; and reverse: 5′-GATACTCCTGAAGGTCTCATAGGT-3′. PCR products were confirmed by their size, as determined by electrophoresis and DNA sequencing.
Cell culture. C2C12 myoblastic cells were purchased from Dainippon Pharmaceutical Co. (Osaka, Japan) and maintained and proliferated at 37˚C with 5% CO2/95% air in Dulbecco's modified Eagle's Medium (DMEM), supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 0.1 mg/mL streptomycin. At a confluence of 100%, C2C12 myoblastic cells were fused by shifting the medium to DMEM containing 2% horse serum. Cells were maintained in 2% house serum (differentiation medium) prior to experiments.
Measurement of myotube diameter. Differentiated myotubes were treated with TNF-a for 48 h. Control cells were given fresh medium every 24 h. For experimental cells, fresh medium and TNF-a were changed every 24 h. Myotubes were photographed at 320 magnification at 72 h post-treatment using a BIOREVO BZ-9000 fluorescent microscope (Keyence, Osaka, Japan). At least 25-100 diameters were measured per group using BIO-REVO BZ-9000 software (Keyence).
Luciferase assay. Myoblasts were transfected using Jet PRIME reagent (Polyplus, Illkirch, France) according to the manufacturer's instructions. Generally, 2310 4 C2C12 cells were seeded into individual wells of 24-well plates 24 h prior to transfection with either the pGL3-3.4 kb atrogin-1 or 24.3 kb MuRF1 promoter construct and pRL-TK (Promega) (1 mg total DNA/well, 1 : 1 reporter: pRL-TK). When the cells reached confluence, the medium was shifted to differentiation medium to induce myotube formation. After being cultured with 2% horse serum-containing media for 72 h, cells were treated with TNF-a or isoflavones for 24 h, and myotubes were lysed and analyzed using the Dual-Luciferase reporter assay system (Promega).
Real-time RT-PCR. Total RNA was extracted from whole cells according to standard protocols (18) . Realtime RT-PCR with SYBR TM Green dye was performed using an ABI 7300 real-time PCR system (Applied Biosystems, Foster City, CA) as described previously (19) . The following oligonucleotide primers were used for amplification: 5′-AGTTCCAGCCGTCTCTGTGT-3′ and 5′-GATCCTTTGGATTCCTGCAA-3′ for mouse SIRT1 cDNA; and 5′-ACCCAGAAGACTGTGGATGG-3′ and 5′-TTCAGCTCTGGGATGACCTT-3′ for mouse GAPDH cDNA.
Immunoblotting. Cells were prepared in 50 mm Tris-HCl buffer, pH 7.5, containing 150 mm NaCl, 1% Triton X-100, and protease inhibitors, and samples were homogenized using a sonicator. The Pierce BCA Assay (Pierce, Rockford, IL) was used to quantify proteins. Protein samples were combined with 43sample buffer (250 mm Tris-HCl, 8% SDS, 40% glycerol, 8% b-mercaptoethanol, 0.02% bromophenol blue) and separated on a polyacrylamide gel. The proteins were transferred to a polyvinylidene difluoride membrane and probed with primary antibody according to the manufacturer's instructions; antibodies used were rabbit polyclonal anti-phospho-AMPKa and rabbit polyclonal anti-AMPKa (Cell Signaling Technology, Beverly, MA) and mouse monoclonal anti-b-actin (Calbiochem, San Diego, CA). Secondary antibodies were anti-rabbit 1 : 5,000 and anti-mouse 1 : 5,000 (Amersham Biosciences, Pescataway, NJ). Membranes were developed using Amersham TM ECL TM western blotting detection reagents (GE Healthcare, Buckinghamshire, England).
Measurement of SIRT1 activity. SIRT1 activity was measured with the SIRT1 direct fluorescent screening assay kit (Cayman, Ann Arbor, MI) as described previously (20) . Briefly, recombinant SIRT1 was pre-incubated with isoflavones or resveratrol for 10 min. Then the substrate, which comprises the acetylated peptide fragment derived from the p53 sequence, was added, and the reaction was allowed to proceed for 45 min. After addition of a stop reagent, the fluorescence was recorded in a microplate reader (Thermo Fisher Scientific; Varioskan Flash, Waltham, MA) with 360 nm excitation and 465 nm emission wave lengths.
Statistical analysis. All data were statistically evaluated by analysis of variance with Excel-Toukei version 6.0 software (Statistics Survey System-development, Tokyo, Japan) and are expressed as mean6SD, n53-6. Individual differences between groups were assessed with Scheffe's multiple range test. Differences were considered significant at p,0.05.
ReSulTS
Elevated concentrations of inflammatory cytokines, especially TNF-a, have been observed in muscle atrophy-related diseases such as cachexia, sepsis, and aging (21) . To assess the effect of cytokines on muscle atrophy, we analyzed changes in the morphological appearance of TNF-a-treated C2C12 myotubes. As Fig. 1 shows, a decreased diameter of TNF-a-treated myotubes occurred in a dose-dependent manner. The thickness of myotubes in the 100 ng/mL TNF-a-treated cultures was reduced in diameter by approximately half compared with the untreated cultures (Fig. 1) . These results are consistent with previous reports that inflammatory cytokines affect muscle atrophy, including degradation of myofibril components.
Proinflammatory cytokines such as TNF-a and TWEAK induce muscle atrophy mediated by activation of the ubiquitin-proteasome and the NFkB pathways (9, 10) . In addition, the MuRF1 promoter is reported to contain functional NFkB binding sites (11) . Therefore, we examined whether the promoter of muscle-specific atrophy-related ubiquitin ligases (atrogenes), including MuRF1 and atrogin-1, responds to activation of NFkB stimulated by TNF-a using a luciferase reporter assay in differentiated C2C12 myotubes. Transcriptional promoter activity of MuRF1 in TNF-a-treated C2C12 myotubes significantly increased compared with that in control cells. On the other hand, there was no significant difference in the promoter activity of atrogin-1 between PBS and TNF-a-treated C2C12 myotubes. These results suggest that MuRF1, but not atrogin-1, is at least in part an important ubiquitin ligase during muscle atrophy associated with inflammatory factors and is regulated by the cytokine/NFkB signaling pathway.
Yeung et al. (13) reported that SIRT1, a nicotinamide adenosine dinucleotide-dependent histone deacetylase, physically interacts with the p65 subunit of NFkB and inhibits transcription by deacetylating p65 at lysine 310. To examine the role of deacetylation of p65 at lysine 310 in MuRF1 promoter activity, we constructed a mutant of p65. TNF-a-induced MuRF1 promoter activity in Mock-transfected cells (Fig. 2) , but MuRF1 promoter activity in p65-transfected cells was significantly increased compared with that in Mock-transfected cells even in treatment with PBS (Fig. 3A) . Additionally, TNF-a treatment further enhanced MuRF1 promoter activity in p65-transfected cells (Fig. 3A) . In contrast, the deacetylated mutant of p65 completely failed to increase MuRF1 promoter activity with or without TNF-a treatment (Fig. 3A) .
Previous research has shown that the protective effects of resveratrol, which stimulates the activity of SIRT in dexamethasone-induced MuRF1 expression, were abolished in myotubes transfected with SIRT1 siRNA (16) . To confirm the effect of SIRT1 on muscle atrophy, we employed the MuRF1 promoter assay using TNF-a-stimulated C2C12 myotubes. Treatment with TNF-a in mock-transfected C2C12 myotubes resulted in an approximately 2-fold increase in MuRF1 promoter activity (Fig. 3B) . Of interest, increased MuRF1 promoter activity was abolished by SIRT1 (Fig. 3B) . These results suggest that the NFkB deacetylation by SIRT1 may be associated with decreased MuRF1 promoter activity.
To determine whether polyphenols other than resveratrol, i.e., isoflavones such as genistein and daidzein, activate SIRT1, we measured the activity of SIRT using a modified sirtuin/NAD 1 -dependent luminogenic system in vitro. As shown in Fig. 4A , SIRT1 was hardly activated by genistein, daidzein, or resveratrol at concentrations up to 100 mm, while activation of SIRT1 significantly increased in the presence of NAD 1 (Fig. 4B) . These results are consistent with previous reports that resveratrol is not a direct activator of SIRT1 enzyme activity (22, 23) . We further examined whether isoflavones affect the expression of SIRT1 in C2C12 myotubes. The amounts of SIRT1 mRNA were gradually increased by isoflavones containing genistein and daidzein (Fig. 4C) . Of note, the expression of SIRT1 mRNA was increased approximately 2-fold in genistein-and daidzein-treated C2C12 myotubes at 100 mm treatment concentrations, as observed in the resveratrol treatment (Fig. 4C) .
Because AMPK induces SIRT1 by elevating the intracellular NAD 1 /NADH ratio (24), we examined whether isoflavones induce the activation of AMPK. Genistein and daidzein induced the phosphorylation of AMPK in a time-dependent manner but did not alter levels of AMPK protein (Fig. 5) . These data show that isoflavones stimulate SIRT1 through activation of AMPK as well as a transcriptional enhancer of SIRT1.
As shown in Fig. 4 , isoflavones exhibited indirect activation of SIRT1 mediated by its increased expression and phosphorylation of AMPK but not its activation directly. To determine the effects of isoflavones on increased MuRF1 expression by TNF-a treatment, we used the MuRF1 promoter assay. At concentrations ranging from 0 to 100 mm, genistein and daidzein dose dependently suppressed MuRF1 promoter activity induced by TNF-a in C2C12 myotubes (Fig. 6A) . The MuRF1 promoter activity was decreased 50% at 40 mm and 86% at 100 mm genistein whereas a decreased activity of approximately 50% required 100 mm daidzein (Fig. 6A) . We also examined whether isoflavones prevented myotube atrophy by TNF-a. TNF-a treatment resulted in a decreased myotube thickness (Fig. 6B ). In parallel with decreased MuRF1 promoter activity, genistein and daidzein blocked TNF-a-induced myotube atrophy (Fig. 6B ).
DISCuSSIon
Our results indicate that the acetylation of NFkB/p65 plays an important role in transcriptional regulation of MuRF1, a muscle atrophy-related ubiquitin ligase induced by inflammatory cytokines. In contrast, TNF-a failed to increase the expression of atrogin-1, which is known as a muscle-specific ubiquitin ligase similar to MuRF1. The promoter region of atrogin-1 lacks the NFkB binding site, although it contains Forkhead box O (FOXO) transcription factors, which cause muscle atrophy (17, 25) . Thus, regulation of MuRF1 mediated by the cytokine/NFkB signaling pathway can be a target for inflammation-related muscle atrophy.
The promoter region of MuRF1 also contains a FOXO response element. FOXO (as well as NFkB) is acetylated by the p300/CREB-binding protein that is its acetyltransferase, regulating FOXO nuclear localization and transcriptional activation of target genes (26) . Although the p65 subunit of NFkB mediated by p300/CBP acetyltransferases increases DNA binding and enhanced transcription of target genes (12) , several reports suggest that the acetylation of FOXO inhibits its transcription activity (27, 28) . Indeed, Bertaggia et al. demonstrated that FOXO3 activity is negatively controlled by acetylation to prevent excessive muscle loss during denervation-induced muscle atrophy (28) . In our results, the transcriptional activity of MuRF1 in TNF-a-treated C2C12 myotubes significantly increased regardless of whether the promoter region of MuRF1 contained a FOXO binding site, compared with control cells. These results suggest that the acetylation of p65, but not FOXO, induced by a cytokine signaling pathway enhances expression of target genes. We found that the isoflavones genistein and daidzein induced the expression of SIRT1 in C2C12 myotubes whereas they did not affect activation of recombinant SIRT1 in vitro. It has been reported that the SIRT1 promoter sequence in the upstream regulatory region contains the estrogen receptor a binding sites (29) . Moreover, the complex of estrogen/estrogen receptor a, which functions as a transcriptional activator by binding to the estrogen response element in the target gene promoter, increases the expression of SIRT1 by directly binding to the SIRT1 promoter. Our finding that the amounts of SIRT1 mRNA were gradually increased by isoflavones in dose-dependent treatment is consistent with previous reports (20) . On the other hand, the estrogen receptor a binding element was not detected on the promoter region until 4.2 kb MuRF1 upstream. Therefore, these findings suggest that an inhibitory effect of isoflavones in upregulated MuRF1 promoter activity stimulated by TNF-a occurs through SIRT1 expression.
Consistent with several recent reports that resveratrol does not affect direct activation of SIRT1 in vitro (22, 23) , we showed that the isoflavones genistein and daidzein as well as resveratrol failed to enhance direct activation of recombinant SIRT1, implying that activators of SIRT1, such as polyphenol, indirectly activate SIRT1. Indeed, genistein and daidzein induced the phosphorylation of AMPK in C2C12 myotubes. AMPK has been shown to activate SIRT1 indirectly by elevating intracellular levels of NAD 1 (24) . We also demonstrated that the activation of recombinant SIRT1 in vitro is induced by NAD
1
. Therefore, our results suggest that enhanced activation of SIRT1 by the isoflavones genistein and daidzein is mediated by indirect pathways.
Phytoestrogenic isoflavones selectively inhibit nuclear NFkB translocation of specific target genes in estrogen receptor-deficient cells, indicating the presence of estrogenic activity-independent pathway (15) . This finding suggests that the inhibitory effect of isoflavones presents not only as upregulation of SIRT1 expression mediated by estrogen receptor a, but also by other pathways. Ji et al. showed that genistein prevents NFkB activation caused by lipopolysaccharide treatment following AMPK activation in RAW264.7 macrophages (30). Consistent with this report, we found that genistein and daidzein activate phosphorylation of AMPK in C2C12 myotubes. It has been proposed that AMPK induces SIRT1 activity by elevating the intracellular NAD 1 /NADH ratio (24) . Thus, isoflavones activate SIRT1 through an AMPK pathway, resulting in inhibition of NFkB activation. Additionally, we concluded that inhibition of NFkB activation by isoflavones occurred by SIRT1 activation through synergism between estrogenic action and phosphorylation of AMPK in muscle cells.
In this study, we report an inhibitory effect of isoflavones on the upregulation of MuRF1-mediated inflammatory signaling in C2C12 myotubes. Our data also suggest that natural isoflavones derived from soy beans provide a therapeutic benefit by activating SIRT1 to prevent inflammation-related muscle atrophy.
